About Us

AzurRx BioPharma is a clinical stage biopharmaceutical company (NASDAQ: AZRX) focused on the development of recombinant proteins for the treatment of gastrointestinal diseases. Our therapeutic products will be administered to patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients). The company is headquartered in New York City, with scientific operations in Langlade, France and clinical operations in Hayward, California.

Stock Quote

AZRX

*Delayed quote courtesy of Google.